A476830 Share Price Performance
₩138,000.00
48000.00 (53.33%)
Price ₩138,000.00
Share Pricen/a
No recently updated narratives available.
Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si, South Korea.